BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20214445)

  • 21. [Micafungin in invasive candidiasis among oncohematological patients].
    Jarque I; Angel Sanz M
    Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics.
    Racil Z; Toskova M; Kocmanova I; Buresova L; Kouba M; Drgona L; Masarova L; Guman T; Tothova E; Gabzdilova J; Forsterova K; Haber J; Ziakova B; Bojtarova E; Rolencova M; Timilsina S; Cetkovsky P; Mayer J
    Leuk Lymphoma; 2013 May; 54(5):1042-7. PubMed ID: 23088794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
    Yeh TC; Liu HC; Hou JY; Chen KH; Huang TH; Chang CY; Liang DC
    Cancer; 2014 Apr; 120(8):1255-62. PubMed ID: 24415457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.
    Jeong SH; Kim DY; Jang JH; Mun YC; Choi CW; Kim SH; Kim JS; Park JS
    Ann Hematol; 2016 Jan; 95(2):337-44. PubMed ID: 26596974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies.
    Toubai T; Tanaka J; Ota S; Shigematsu A; Shono Y; Ibata M; Hashino S; Kondo T; Kakinoki Y; Masauzi N; Kasai M; Iwasaki H; Kurosawa M; Asaka M; Imamura M
    Intern Med; 2007; 46(1):3-9. PubMed ID: 17202726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
    Xu SX; Shen JL; Tang XF; Feng B; Xu HQ
    Eur Rev Med Pharmacol Sci; 2016; 20(2):381-90. PubMed ID: 26875911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders.
    Yoshida M; Tamura K; Imamura M; Niitsu Y; Sasaki T; Urabe A; Ohyashiki K; Naoe T; Kanamaru A; Tanimoto M; Masaoka T
    Ann Hematol; 2012 Mar; 91(3):449-57. PubMed ID: 21894476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT.
    Park HJ; Park M; Han M; Nam BH; Koh KN; Im HJ; Lee JW; Chung NG; Cho B; Kim HK; Yoo KH; Koo HH; Kang HJ; Shin HY; Ahn HS; Lim YT; Kook H; Lyu CJ; Hah JO; Park JE; Lim YJ; Seo JJ
    Bone Marrow Transplant; 2014 Sep; 49(9):1212-6. PubMed ID: 25000455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
    Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
    J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
    van Burik JA; Ratanatharathorn V; Stepan DE; Miller CB; Lipton JH; Vesole DH; Bunin N; Wall DA; Hiemenz JW; Satoi Y; Lee JM; Walsh TJ;
    Clin Infect Dis; 2004 Nov; 39(10):1407-16. PubMed ID: 15546073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of micafungin for febrile neutropenia in pediatric patients with hematological malignancies: a multicenter prospective study.
    Kobayashi R; Suzuki N; Yoshida M; Iizuka S; Suzuki D; Sano H; Kudoh T
    J Pediatr Hematol Oncol; 2013 Oct; 35(7):e276-9. PubMed ID: 23743960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders.
    Tamura K; Urabe A; Yoshida M; Kanamaru A; Kodera Y; Okamoto S; Maesaki S; Masaoka T
    Leuk Lymphoma; 2009 Jan; 50(1):92-100. PubMed ID: 19172498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
    Timsit JF; Azoulay E; Schwebel C; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Argaud L; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Maubon D; Jullien V; Wolff M;
    JAMA; 2016 Oct; 316(15):1555-1564. PubMed ID: 27706483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin.
    Vena A; Bouza E; Álvarez-Uría A; Gayoso J; Martín-Rabadán P; Cajuste F; Guinea J; Gómez Castellá J; Alonso R; Munoz P
    Clin Microbiol Infect; 2017 Dec; 23(12):1000.e1-1000.e4. PubMed ID: 28506782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients.
    Lehrnbecher T; Groll AH
    Pediatr Blood Cancer; 2010 Aug; 55(2):229-32. PubMed ID: 20583216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials.
    Lee CH; Lin JC; Ho CL; Sun M; Yen WT; Lin C
    PLoS One; 2017; 12(7):e0180050. PubMed ID: 28700646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis.
    Imataki O; Kubota Y; Ohnishi H; Kitanaka A; Ishida T; Tanaka T
    Support Care Cancer; 2011 Oct; 19(10):1657-65. PubMed ID: 20830490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
    Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
    Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.